<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977193</url>
  </required_header>
  <id_info>
    <org_study_id>LY011C1002</org_study_id>
    <nct_id>NCT04977193</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma</brief_title>
  <official_title>to Evaluate the Safety and Efficacy of LY011 Cell Injection（Targeting CLDN 18.2 Chimeric Antigen Receptor T Cells） in the Treatment of Advanced Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Longyao Biotechnology Inc., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Longyao Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective to evaluate the safety and efficacy of ly011 cell injection in the treatment of&#xD;
      advanced gastric adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerable dose（MTD）</measure>
    <time_frame>1month</time_frame>
    <description>MTD determination will based on the incidence of reported adverse events (including dose-limiting toxicities) and abnormal laboratory test results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>2 years</time_frame>
    <description>AEs according to CTCAE v 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response rate（ORR）</measure>
    <time_frame>2 years</time_frame>
    <description>the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time 0 to the last time point (AUC0-t)</measure>
    <time_frame>1 years</time_frame>
    <description>Area under the curve from time 0 to the last time point for serum CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL)</measure>
    <time_frame>1 years</time_frame>
    <description>Apparent clearance for serum CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>1 years</time_frame>
    <description>Maximum concentration for serum CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T½）</measure>
    <time_frame>1 years</time_frame>
    <description>Half-life for serum CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC0-inf)</measure>
    <time_frame>1 years</time_frame>
    <description>Area under the serum concentration-time curve for serum CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>1 years</time_frame>
    <description>Time to maximum concentration for serum CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz)</measure>
    <time_frame>1 years</time_frame>
    <description>Terminal elimination rate constant for serum CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve above baseline of ANC [ANC_AUC(0-tlast)]</measure>
    <time_frame>1 years</time_frame>
    <description>Area under the curve above baseline of ANC for serum CAR-T cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Advanced Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY011</intervention_name>
    <description>CAR-T</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be enrolled in this study:&#xD;
&#xD;
          1. They were 18 to 70 years old, male or female; Histologically confirmed recurrent or&#xD;
             metastatic advanced gastric adenocarcinoma (including gastric adenocarcinoma at the&#xD;
             gastroesophageal junction);&#xD;
&#xD;
          2. Claudin 18.2 IHC staining was positive in tumor tissues;&#xD;
&#xD;
          3. Patients with advanced gastric adenocarcinoma who are not cured by second-line&#xD;
             chemotherapy and unwilling to accept second-line chemotherapy after failure of&#xD;
             first-line chemotherapy;&#xD;
&#xD;
          4. Life expectancy &gt; 12 weeks;&#xD;
&#xD;
          5. According to RECIST 1.1, there was at least one measurable tumor target (≥ 10 mm);&#xD;
&#xD;
          6. ECoG scores at screening, 24 hours before puncture and baseline (before treatment)&#xD;
             were 0-1;&#xD;
&#xD;
          7. Adequate organ function;&#xD;
&#xD;
          8. For women of childbearing age with negative pregnancy test or male subjects, effective&#xD;
             and reliable contraceptive methods must be adopted until 30 days after the end of&#xD;
             treatment;&#xD;
&#xD;
          9. Have enough understanding ability to voluntarily sign informed consent to participate&#xD;
             in clinical research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who met any of the following criteria were not included in this study:&#xD;
&#xD;
          1. The patients received the following anti-tumor treatment before transplantation:&#xD;
&#xD;
               -  Cytotoxic treatment within 14 days&#xD;
&#xD;
               -  Small molecule targeted therapy for 14 days or at least 5 half lives, whichever&#xD;
                  is longer&#xD;
&#xD;
               -  Experimental drug treatment within 28 days (if the above treatment is also&#xD;
                  experimental drug treatment, the 28 day flushing period should be followed)&#xD;
&#xD;
               -  The patients were treated with monoclonal antibody within 28 days&#xD;
&#xD;
               -  Immunomodulatory therapy within 7 days&#xD;
&#xD;
               -  Radiotherapy within 14 days&#xD;
&#xD;
          2. Pregnant or lactating women;&#xD;
&#xD;
          3. Serological positive for HIV, Treponema pallidum or HCV;&#xD;
&#xD;
          4. Any uncontrollable active infection, including but not limited to active tuberculosis&#xD;
             and HBV infection (HBsAg positive, HBcAb positive and HBV DNA positive);&#xD;
&#xD;
          5. The subjects were judged as clinically significant thyroid dysfunction by the&#xD;
             investigators (serum thyroid hormone determination TT4, TT3, FT3, FT4, serum thyroid&#xD;
             stimulating hormone TSH) and were not suitable to participate in this study;&#xD;
&#xD;
          6. The side effects caused by previous treatment did not recover to CTCAE ≤ 1;&#xD;
&#xD;
          7. Subjects who are currently using steroids throughout the body within 7 days before de&#xD;
             pregnancy; Recent or recent use of inhaled steroids was not excluded;&#xD;
&#xD;
          8. Any previous treatment for claudin 18.2;&#xD;
&#xD;
          9. Previous allergy to immunotherapy and related drugs, severe allergy or allergic&#xD;
             history;&#xD;
&#xD;
         10. T cells (including car-t and tcr-t) that have been modified by chimeric antigen&#xD;
             receptor;&#xD;
&#xD;
         11. The subjects had untreated or symptomatic brain metastases;&#xD;
&#xD;
         12. The subjects had central or extensive lung metastases;&#xD;
&#xD;
         13. The subjects had heart disease requiring treatment or lost control of hypertension&#xD;
             after treatment (blood pressure &gt; 160 mmHg / 100 mmHg);&#xD;
&#xD;
         14. Subjects with a history of organ transplantation or waiting for organ transplantation;&#xD;
&#xD;
         15. There is no other serious disease that may restrict the subjects to participate in&#xD;
             this trial;&#xD;
&#xD;
         16. The researcher assessed that the subjects were unable or unwilling to comply with the&#xD;
             requirements of the study protocol;&#xD;
&#xD;
         17. Blood oxygen saturation ≤ 95% before treatment (receiving finger oxygen test);&#xD;
&#xD;
         18. Before pretreatment, subjects developed new arrhythmias, including but not limited to&#xD;
             arrhythmias that could not be controlled by drugs, hypotension requiring vasopressin,&#xD;
             bacterial, fungal or viral infections requiring intravenous antibiotics; The&#xD;
             creatinine clearance rate was less than 40 ml / min; Investigators concluded that the&#xD;
             subject was not suitable for further study. Subjects who use antibiotics to prevent&#xD;
             infection can continue the trial if the researcher makes a judgment;&#xD;
&#xD;
         19. There are signs of central nervous system diseases or abnormal results of nervous&#xD;
             system tests, which are of clinical significance;&#xD;
&#xD;
         20. The subjects were suffering from or had other malignant tumors that could not be cured&#xD;
             within 3 years, except for cervical cancer in situ or basal cell carcinoma of skin;&#xD;
&#xD;
         21. known hypersensitivity to excipients and related adjuvants (including but not limited&#xD;
             to dimethyl sulfoxide and dextran-40) of the study drug;&#xD;
&#xD;
         22. other conditions considered unsuitable by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Song, Chief physician</last_name>
      <phone>0516-85609999</phone>
      <email>xyfyll2297@163.com</email>
    </contact>
    <investigator>
      <last_name>June Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

